Sydney, June 23, 2026, 06:08 AEST
- Pro Medicus finished Monday at A$174.64, gaining 1.06% while the Australian healthcare sector lost 1.3%.
- The stock dropped out of the S&P/ASX 50, but stayed in the ASX 100, landing it in the S&P/ASX MidCap 50.
- VanEck’s MVE fund reported holding 82,490 PME shares for A$14.4 million, about 19% of Monday’s trading volume.
Pro Medicus (ASX:PME) gained A$1.84 to A$174.64 Monday after it dropped out of Australia’s large-cap benchmark, with the share move defying the usual index effect. Trading in the cash market was shut at press time, with pre-open set for 7 a.m. and regular session due about 10 a.m. AEST.
S&P Dow Jones Indices has dropped Pro Medicus from the S&P/ASX 50, effective before Monday’s open, but Pro Medicus stays in the S&P/ASX 100. The company’s removal from the top 50 means it will shift into the MidCap 50, which tracks ASX 100 stocks not in the top 50. So instead of falling out of all major index portfolios, Pro Medicus lands in the mid-cap benchmark.
VanEck’s latest holdings file gives a look at the scale of passive buying. Its S&P/ASX MidCap ETF (MVE) owned 82,490 Pro Medicus shares worth A$14.41 million, or 2.93% of the fund, as of June 22. That’s about 19% of Monday’s 436,640 Pro Medicus shares traded. VanEck doesn’t say when these shares were bought, so it’s not clear if they were picked up during Monday’s session. But the index demotion put a new passive buyer in the mix, not just sellers.
Pro Medicus beat the market. The S&P/ASX 200 dropped 0.14% and healthcare lost 1.3%, but 4DMedical was up 4%. ResMed added 1%. That’s some rotation inside the sector, though Pro Medicus also had help from a rare two-way move in the index.
Operating conditions are steady. Pro Medicus CEO Sam Hupert told investors this month the company booked over A$400 million in total contract value so far this financial year. “FY26 will be one of our biggest years of sales in our company history,” he said. The deal pipeline still targets academic hospitals, major health networks, and private radiology groups. ASX Announcements
Pricing may turn out to be a more lasting driver than contract win news. The latest renewals with Allegheny Health Network for A$28 million and Ohio State University Wexner Medical Center at A$16 million came with bigger minimums and bumped-up transaction fees, plus new software modules. Because pricing is tied to imaging transactions, but with minimums locked in, revenue moves mostly with customer imaging volumes. That lets the company pull more revenue from customers like these without needing a new tender.
TidalHealth signed a seven-year contract worth A$16 million to add cardiology imaging to Pro Medicus’ cloud-based viewer, workflow, and archive products. This pushes more software into each hospital, with workflow and cardiology now joining the core radiology viewer and boosting the revenue chance per site.
Index buying won’t keep a lasting floor under prices. After the rebalance trades wrap up, fresh MVE demand will tie back to fund flows. The stock is trading at about 77.9 times trailing earnings. Morningstar’s Brian Han held his much lower A$54 fair value. “Shares remain overvalued, despite the recent correction, as we think the core addressable market is limited,” Han said. He pointed to tougher competition from Sectra. If hospitals roll out software more slowly or scan growth falls short, or if the company misses out on tenders, the valuation could take a hit. Tradingview
Tuesday brings a test for Pro Medicus. The question is if the stock keeps its Monday gain after the initial run of index-driven orders. If prices hold steady on lower volumes, investors may be looking more at contract repricing and growth in modules. If shares reverse, it signals more of a technical bounce.
